profit from every $100 of sales.
$0$100
West Pharmaceutical Services
$416.42+1.24% today
+56.2% in 1 year
1-year low $230.951-year high $416.67
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $58.76 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What West Pharmaceutical Services sold, what it kept, and what it did with the cash.
Sales went from $2.89 billion in 2022 to $3.07 billion in 2025, with $494 million of profit last year.
SalesProfit
West Pharmaceutical Services handed back 42% of the cash it generated last year.
Buybacks $137M$61M
Free cash flow 2025$469M
Bought back its own shares$137M
Paid as dividends$61M
Cash vs. debt$791M vs. $321M
West Pharmaceutical Services vs. similar companies
West Pharmaceutical Services grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| West Pharmaceutical Services | 58.8× · Expensive | ||
 ResMed | 22.1× · Fair price | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet | ||
 The Cooper Companies | 31.8× · Expensive |
AI analysis
An AI analyst reads West Pharmaceutical Services's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,147 | 2,832 | 2,887 | 2,950 | 2,893 | 3,074 | |
| 768 | 1,176 | 1,136 | 1,129 | 999 | 1,104 | |
| – | – | 761 | 707 | 591 | 636 | |
| 519 | 879 | 808 | 844 | 744 | 773 | |
| 346 | 662 | 586 | 593 | 493 | 494 | |
| 4.57 | 8.67 | 7.73 | 7.88 | 6.69 | 6.79 | |
| 35.8% | 41.5% | 39.4% | 38.3% | 34.5% | 35.9% | |
| – | – | 26.4% | 24.0% | 20.4% | 20.7% | |
| 16.1% | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 2,794 | 3,314 | 3,617 | 3,830 | 3,643 | 4,270 |
| Cash | 616 | 763 | 894 | 854 | 485 | 791 |
| Total debt | 326 | 325 | 318 | 309 | 302 | 321 |
| Total liabilities | 939 | 978 | 932 | 949 | 961 | 1,094 |
| 1,855 | 2,335 | 2,685 | 2,881 | 2,682 | 3,176 | |
| 76 | 76 | 76 | 75 | 74 | 73 | |
| 14.8% | 22.5% | 18.1% | 17.5% | 15.6% | 13.6% | |
| 18.7% | 28.3% | 21.8% | 20.6% | 18.4% | 15.5% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 473 | 584 | 724 | 777 | 653 | 755 | |
| 174 | 253 | 285 | 362 | 377 | 286 | |
| 298 | 331 | 439 | 415 | 276 | 469 | |
| Dividends paid | 48 | 51 | 54 | 57 | 59 | 61 |
| 116 | 137 | 222 | 451 | 567 | 137 | |
| 34 | 38 | 24 | 23 | 19 | 24 |
Valuation
- 58.8×
- –
- 7.13
- 7.2×
- 9.4×
- 61.9×
- 36.9×
- 1.6%
- 1.7%
- 0.3%
Profitability
- 35.9%
- 20.7%
- 16.1%
- 24.8%
- 15.2%
- 18.6%
- 17.9%
- 13.2%
- 19.4%
- 2.3%
Growth
- +7.4%
- +8.2%
- +69.6%
- +5.5%
- −0.7%
Financial health
- -0.3×
- 0.11
- 7.7%
- 3,328.0×
- 2.71
- 2.04
- 0.78
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 15%of 947
Top 23%of 874
Bottom 19%of 565
Bottom 36%of 869
Top 46%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 23, 2026 | 2.13 | 1.68 | +26.8% |
| Feb 12, 2026 | 2.04 | 1.83 | +11.5% |
| Oct 23, 2025 | 1.96 | 1.68 | +16.7% |
| Jul 24, 2025 | 1.84 | 1.51 | +21.9% |
| Apr 24, 2025 | 1.45 | 1.22 | +18.9% |
| Feb 13, 2025 | 1.82 | 1.71 | +6.4% |
| Oct 24, 2024 | 1.85 | 1.50 | +23.3% |
| Jul 25, 2024 | 1.52 | 1.74 | −12.6% |
0.3%of the share price, paid each year
On $1,000 invested$3a year at today's yield, before tax
+5.5%2020 to 2025
Raised10 yearsin a row, in our data
Paid per share, each year
$0.45 in 2015 → $0.85 in 2025
How safe it looks
12.4% of its profit
Room to growStretchedMore than it earns: 13.1%
News
Nvidia weighs playing the cosigner for Nscale’s AI data center in West VirginiaYahoo Finance · Oct 31, 2026East West raises 2026 NII growth outlook to 9%-10% while cutting net charge-off guide to 15-20 bpsSeeking Alpha · Oct 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
59No pass
Benjamin Graham
45No pass
Philip Fisher
52No pass
Peter Lynch
33No pass
Joel Greenblatt
13No pass
Charlie Munger
63Pass
Terry Smith
54No pass
Questions about West Pharmaceutical Services
Is West Pharmaceutical Services a good stock to buy?
A solid business, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the West Pharmaceutical Services AI analysis
What does West Pharmaceutical Services do?
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It is in Medical - Instruments & Supplies, based in Exton, PA, United States, with 10,800 employees.
Does West Pharmaceutical Services pay a dividend?
Yes. At today's price the dividend is 0.3% a year, about 12% of its yearly profit. In 2025 it paid out $61.2 million in dividends.
Is West Pharmaceutical Services stock halal?
Yes. West Pharmaceutical Services passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has West Pharmaceutical Services stock done over the past year?
Up 56.2% over the past twelve months, to $416.42. It traded between $230.95 and $416.67, close to its high.
Who are West Pharmaceutical Services's competitors?
The largest listed companies in the same industry are ResMed, Hologic, Baxter International and The Cooper Companies. The peers table on this page compares their profit, growth and price with West Pharmaceutical Services's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.